- Cambridge, Massachusetts, United States
- Full-time
- $100K–$120K per year
- 0–4 years
Lead mechanistically novel preclinical studies in multiple myeloma to advance translational oncology research.
Compensation
Compensation for this role, based on years of experience after obtaining PhD, is a minimum of $99,900 up to a maximum of $120,000 + short-term incentive. Some relocation supplements depend on distance and location at the employer's discretion.
Responsibilities
- Lead in vivo studies in syngeneic and xenograft mouse models to establish and characterize the non-cancer cell autonomous function of a first-in-class kinase inhibitor in multiple myeloma
- Dissect the mechanistic contribution of individual innate immune cell types through CRISPR-based models, immune cell depletion, and reconstitution experiments
- Apply advanced immunophenotyping and transcriptomic platforms, including CyTOF, single-cell RNA-seq, and CITE-seq, to define pathway modulation across innate immune compartments
- Evaluate rational combination strategies with T-cell engagers and CAR-T therapies in relevant preclinical models
- Drive a clear publication plan, including a first-author review in Year 1 and first-author research manuscripts over the three-year term
Requirements
- Ph.D. in Immunology, Hematology, Cancer Biology, Molecular or Cell Biology, or a related field
- Nice to have: xenograft mouse models (SCID, NSG)
- Nice to have: immune cell depletion or reconstitution approaches
- Nice to have: NK cell biology